SignalFDA/Bio

Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug

Mid-stage bladder cancer trial readout catalysts Tyra Bio's rise.

What changed

Mid-stage bladder cancer trial readout catalysts Tyra Bio's rise.

Why it matters

Mid-stage bladder cancer trial readout catalysts Tyra Bio's rise. — impact context not separately stored; see What changed.

Sources